N/A N=28 Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
Macular Degeneration
Primary: Discomfort Associated With the Intravitreal Injection — 3; 2.3; 2.8; 3.1 units on a scale — p=0.28
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=119 A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
Cystic Fibrosis
Primary: Number of Participants With 5% or Greater Relative Change in FEV1 (Liters) From Baseline to Day 28 — 22; 17 Participants — p=0.811
Phase 1 N=7 A Study of LY3113593 in Participants With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1 Participants
Phase 3 N=655 Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Number of Participants With Early Clinical Response — 268; 266; 23; 19 Participants
Phase 3 N=229 Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat
Sore Throat
Primary: Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS) — 89.47; 75.65; 7.02; 19.13 Percentage of Participants — p=0.00001
Phase 1 N=357 Use of the VisuMax™ Femtosecond Laser
Myopia
Primary: Effectiveness- Predictability of Participant Refractive Outcomes — 291; 306 Participants
Phase 3 N=51 Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Reduction in Heavy Drinking in Patients With HIV
Primary: HAART Adherence — 7; 4; 6; 4 Participants
N/A N=387 Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "
Hypertension
Primary: Changes From Baseline in Blood Pressure on Final Assessment Point (up to Week 24) Measured at the Medical Institution — -10.5; -5.1 Millimeter of Mercury (mmHg)
Phase 4 N=350 Hepatitis B Booster Study in Adolescence
Hepatitis B
Primary: Serum Anti-HBs Concentration 12 IU/L or Greater — 30; 76 Participants
Phase 3 N=197 ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183 — -0.82; 8.39 percent change
Phase 1 N=16 Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AEs — 4; 12 Participants
Phase 2 N=105 Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
Macular Edema
Primary: Change From Baseline in Central Subfield Foveal Thickness (CSFT) at Week 12 — -6.19; 10.26 Micrometre [μm] — p=0.3199
Phase 2 N=11 Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Phase 3 N=254 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
GVHD · Adult Acute Myeloid Leukemia · Adult Acute Lymphoid Leukemia
Primary: Number of Participants With First Occurrence of Moderate to Severe Chronic GVHD According to 2005 NIH Criteria as Determined by the Independent Endpoint Committee or…
Phase 4 N=155 Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty
Osteoarthritis
Primary: Change in VAS Pain Scores — 3.0; 3.0; 2.7; 3.9 scores on a scale